错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

Die primäre retroperitoneale Lymphadenektomie beim testikulären Keimzelltumor im klinischen Stadium IIA/B – Renaissance einer etablierten Therapie?

  • Julian Heidenreich,
  • Ruben Gößmann,
  • Felix Seelemeyer,
  • David Pfister,
  • Pia Paffenholz,
  • Axel Heidenreich

摘要

Background

The guideline-recommended treatment of choice for clinical stage IIA/B testicular germ cell tumors is chemotherapy with three cycles of PEB/four cycles of PE or, alternatively, radiation for seminomas. Despite their high curative efficacy, both options are associated with significant long-term toxicities. We evaluated the functional and oncological outcomes of primary retroperitoneal lymph node dissection (RPLND) as a therapeutic alternative.

Patients and methods

Between 2018 and 2022, 76 patients (n = 34 seminomas, n = 42 nonseminomas) underwent primary RPLND for marker-negative clinical stage IIA/B testicular germ cell cancer. All patients underwent nerve-sparing RPLND with a unilateral or bilateral template dissection and had a follow-up ≥ 3 months. None of the patients received adjuvant chemotherapy. In 24 patients, the serum concentration of miR371a-3p was evaluated preoperatively. Follow-up was performed according to EAU guidelines.

Results

Median age and median follow-up were 30.1 (17–62) years and 29.3 (3–72) months, respectively. Mean operation time, blood loss, and duration of hospitalization were 131 (105–195) min, < 150 ml, and 4.5 (3–9) days, respectively. A Clavien-Dindo IIIa complication was experienced by 8 (10.9%) patients. Antegrade ejaculation was preserved in 90.8%. A mean number of 19 (7–68) lymph nodes were dissected. The mean number of positive lymph nodes was 1.1 (1–5), and the mean diameter of positive lymph nodes was 2.4 (0.8–4.6) cm. Eleven (14.5%) patients had stage pN0 (3/34 seminomas, 8/42 nonseminomas). In 24/27 patients (88.9%) miR371 was positive, and it was negative in 4/4 with pN0 and 3/3 (100%) with teratoma. An outfield relapse was experienced by 7 patients (9.2%), who then received salvage chemotherapy.

Conclusion

Primary RPLND for marker-negative clinical stage IIA/B germ cell tumors results in high cure rates without adjuvant chemotherapy and is associated with a low rate of complications if performed in experienced hands. Therefore, primary RPLND should be included in the management of these patients.